Cipla Limited (NSE: CIPLA) and Mankind Pharma (NSE: MANKIND) are both listed in the Medicinal Chemicals and Botanical Products industry. Cipla has a market capitalisation of ₹1,12,054 Cr and Mankind Pharma ₹1,02,485 Cr, as of 9 Nov 2026. Their P/E ratios are 28.9 and 53.6 respectively. Return on equity is 11.74% for Cipla and 12.45% for Mankind Pharma. Over one year, Cipla's share price is down 7.1% and Mankind Pharma's is up 11.2%.
| Metric | Cipla | Mankind Pharma |
|---|---|---|
| NSE Symbol | CIPLA | MANKIND |
| BSE Code | 500087 | 543904 |
| Share Price | ₹1,403.80 | ₹2,668.30 |
| Market Cap | ₹1,12,054 Cr | ₹1,02,485 Cr |
| P/E Ratio | 28.9 | 53.6 |
| Return on Equity | 11.74% | 12.45% |
| Return on Assets | 7.58% | 6.31% |
| Dividend Yield | 0.94% | 0.08% |
| Beta (1Y) | 0.01 | 0.43 |
| 1-Year Price Change | -7.1% | +11.2% |
| 3-Month Price Change | -4.4% | +9.4% |
| 52-Week Range | ₹1,165.70 – ₹1,539.70 | ₹1,909.70 – ₹2,705.00 |
| Latest Quarter | Q2 FY27 | Q2 FY27 |
| Quarterly Revenue | ₹7,404 Cr | ₹4,338 Cr |
| Quarterly Net Profit | ₹852 Cr | ₹716 Cr |
| Net Margin | 11.5% | 16.5% |
| EPS (Basic, Quarter) | ₹10.86 | ₹17.23 |
| Results Basis | consolidated | consolidated |
| Headquarters | Mumbai, Maharashtra | New Delhi, Delhi |
The figures sit side by side and are not ranked. Quarterly figures are in ₹ crore, parsed from each company's exchange filing (XBRL); the two companies' latest quarters can differ.
Cipla Limited, together with its subsidiaries, manufactures, develops, sells, and distributes pharmaceutical products in India, the United States, South Africa, and internationally. The company operates through Pharmaceuticals and New Ventures segments. It offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations for various therapeutic areas, such as MI, angina, heart disease, pulmonary disease, kidney failure, Alzheimer’s disease, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, central nervous system, HIV/AIDS, respirator…
Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of anti-infective, cardiovascular, gastrointestinal, gynaecology, anti-diabetic, dermatology, pain/analgesics, neuro/CNS, vitamins/minerals/nutrients, respiratory diseases, etc. It also provides consumer healthcare products, such as condoms, pregnancy detection kits, oral contraceptives, antacid powders, vitamin and mineral supplements, and anti-acne preparations…
Cipla has a market capitalisation of ₹1,12,054 Cr, against ₹1,02,485 Cr for Mankind Pharma as of 9 Nov 2026, so the two are about the same size by market cap.
Cipla has a P/E of 28.9 and Mankind Pharma a P/E of 53.6 as of 9 Nov 2026.
Cipla has a return on equity of 11.74% and Mankind Pharma 12.45%.
Cipla's share price is down 7.1% over one year and Mankind Pharma's is up 11.2%.
Cipla reported revenue of ₹7,404 Cr and net profit of ₹852 Cr for Q2 FY27. Mankind Pharma reported revenue of ₹4,338 Cr and net profit of ₹716 Cr for Q2 FY27. Figures are parsed from each company's exchange filing.
Both are classified under Pharmaceuticals > Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products on FinBizNet.
No. The page lays the two companies' published figures side by side and draws no conclusion from them. It is descriptive market data, not investment advice.
Data as of 9 Nov 2026. Descriptive market data only — not investment advice.